Lung health in LMICs: tackling challenges ahead - Authors' reply
- PMID: 34364524
- DOI: 10.1016/S0140-6736(21)01252-6
Lung health in LMICs: tackling challenges ahead - Authors' reply
Conflict of interest statement
GBM reports grants and advisory board fees from AstraZeneca; and grants from GSK Australia. KM reports advisory board fees from AstraZeneca. All other authors declare no competing interests.
Comment on
-
Lung health in LMICs: tackling challenges ahead.Lancet. 2021 Aug 7;398(10299):488-489. doi: 10.1016/S0140-6736(21)01230-7. Lancet. 2021. PMID: 34364520 No abstract available.
-
Lung health in LMICs: tackling challenges ahead.Lancet. 2021 Aug 7;398(10299):489-490. doi: 10.1016/S0140-6736(21)01232-0. Lancet. 2021. PMID: 34364521 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
